Acc Consensus On New Diabetes Drugs To Reduce Cv Outcomes | Latest News RSS feed

Acc Consensus On New Diabetes Drugs To Reduce Cv Outcomes - Latest News


ACC offers guidance on using diabetes drugs for CV event reduction

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients w... read more

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

(HealthDay News ... (CV) benefit and should be used for reducing CV risk in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), according to a report of the America... read more

ACC recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes

The 2018 ACC Expert Consensus statement emphasizes the need for a collaborative treatment approach by healthcare providers to reduce cardiovascular ... care and outcomes of people with type 2 diabetes ... read more

Looking for another news?


New EASD-ADA consensus guidelines on managing hyperglycaemia in type 2 diabetes launched at EASD meeting

Following a review of the latest evidence —including a range of recent trials of drug and lifestyle interventions—the European Association for the Study of Diabetes ... They add: "New questions arise ... read more


No Near-Term Cure For Repatha And Praluent Discontents

It is getting increasingly difficult to find good news for new cholesterol-lowering drugs Repatha and Praluent ... Repatha would reduce cardiovascular events and deaths by 30% based on a 64% reduction ... read more

Liraglutide shows cardiovascular benefit in routine practice

The research comes on the heels of a new expert consensus document released by the American College of Cardiology, which gave liraglutide the nod as the preferred GLP-1RA to reduce cardiovascular risk ... read more

Study: TAVR Success Tied to Experience With SAVR

Note that the association between baseline SAVR quality and subsequent TAVR outcomes persisted after adjustment ... Association for Thoracic Surgery, the American College of Cardiology, the Society fo... read more

Rapid Decline in Lung Function Linked to CVD Risk

A rapid decline in lung function is associated with a higher incidence of cardiovascular disease (CVD), particularly heart failure, a new study ... heart rate, diabetes, hypertension, low-density lipo... read more

Should I Take a Statin? What You Need to Know About the New Cholesterol Guidelines

Using the new model, the AHA and ACC recommend that everyone who plugs their information into the calculator and has a risk of having a heart event or stroke that is 7.5% or higher in the next 10 year... read more

Novo Nordisk: Pick Up This Diabetes Leader In 2018

New ... ability to reduce cardiovascular events in type 2 diabetes patients. Already approved in USA and Europe, the drug awaits regulatory decision in Japan in 2018. By mid of 2018, Novo Nordisk now ... read more

MED Cardiologist on What New Blood Pressure Recommendations Mean

American College of Cardiology issues new ... cardiovascular disease) risk score. And that looks at your age, gender, cholesterol level, presence of diabetes, blood pressure, whether or not you’re bei... read more

Niacin too dangerous for routine cholesterol therapy

All patients in the trial were already being treated with a statin medication. Niacin did not reduce ... cardiovascular outcomes nor does lowering triglyceride levels, Lloyd-Jones points out. "The rec... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us